Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year.

Carter JP, Foard D, Rannigan L, Aliaz K, Mahmood S, Sachchithanantham S, Fontana M, Quarta C, Martinez De Azcona Naharro A, Youngstein T, Rezk T, Wechalekar A, Whelan C, Lachmann H, Hawkins P, Gillmore J, Lane T.

Amyloid. 2017 Mar;24(sup1):72-73. doi: 10.1080/13506129.2017.1295944. No abstract available.

PMID:
28434320
2.

Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.

Sachchithanantham S, Offer M, Venner C, Mahmood SA, Foard D, Rannigan L, Lane T, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD.

Haematologica. 2015 Nov;100(11):1469-76. doi: 10.3324/haematol.2015.128025. Epub 2015 Aug 20.

3.

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.

Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Roussel M, Rannigan L, Gibbs SDj, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD.

Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5. No abstract available.

4.

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.

Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD.

Leukemia. 2014 Dec;28(12):2304-10. doi: 10.1038/leu.2014.218. Epub 2014 Jul 16.

PMID:
25027514
5.

Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.

Mahmood S, Venner CP, Sachchithanantham S, Lane T, Rannigan L, Foard D, Pinney JH, Gibbs SD, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Br J Haematol. 2014 Sep;166(6):842-8. doi: 10.1111/bjh.12973. Epub 2014 Jun 13.

PMID:
24930361
6.

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G.

Blood. 2013 Apr 25;121(17):3420-7. doi: 10.1182/blood-2012-12-473066. Epub 2013 Mar 11.

PMID:
23479568
7.

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.

Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Blood. 2012 May 10;119(19):4387-90. doi: 10.1182/blood-2011-10-388462. Epub 2012 Feb 13.

PMID:
22331187

Supplemental Content

Loading ...
Support Center